Asian Journal of Nuclear Medicine

Volume 2 Number 1, March 2002


遼寧省腫瘤醫院核醫學科,瀋陽 110042,中國

目的 評價153Sm-EDTMP治療乳腺癌骨轉移的臨床價值。方法 對438例臨床確診為乳腺癌骨轉移患者進行治療,153Sm-EDTMP用量按25.9MBq/kg體重靜脈注射給藥,每月一次,3∼4次為一療程。要求治療前患者白細胞>3.5×109/L,血紅蛋白>90g/L,血小板>9.0×1010/L。結果 根據患者疼痛緩解程度、活動量、止痛藥用量和一般狀況進行評定,骨痛完全緩解佔52.7%(231/438);部分緩解33.8%(148/438);無效13.5%(59/438);其中52例治療後骨顯像示骨轉移灶好轉。結論153Sm-EDTMP治療乳腺癌骨轉移有明顯療效,可改善患者生活質量,無明顯骨髓抑制,可重複使用。


The value of Samarium-153-EDTMP in breast cancer with bone metastases

Chen Lili, Xu Hongying, Yang Yanping, Yu Tong, Yu Dongni, Guan Xiaoguang
Liaoning Hospital of Oncology, Shenyang 110042, China

Objective: This study was to evaluate the efficacy of Samarium-153-EDTMP in breast cancer with bone metastases. Methods: 438 cases with advanced breast cancer that had metastatic bone pain were treated with 153Sm-EDTMP at a dosage of 25.9 MBq/Kg once a month, One course of treatment was 3 to 4 times. Results: The results were evaluated according to the degree of pain relief, mobility, analgesic intake and general feeling. 52.7% (231/438) of patients got complete remission and 33.8% (148/438) incomplete remission. There was no response in the remaining 13.8% (59/438). 52 cases had improved bone scan findings. Conclusions: Palliative treatment of metastatic bone pain from breast cancer with 153Sm-EDTMP improves the quality of life and may be safely repeated with the same benefit and without significant myelosuppression.

Key Words: Breast cancer; Bone metastases; 153Sm-EDTMP; Treatment

Back to Previous Page